Radiotherapy & Oncology
Volume 96, Issue 1 , Pages 1-5 , July 2010

Fractionation in prostate cancer – Is it time after all?

  • Michael Baumann

      Affiliations

    • Department of Radiation Oncology and OncoRay Center for Radiation Research in Oncology, University of Technology, Dresden, Germany
    • Corresponding Author InformationCorresponding author. Address: Department of Radiation Oncology, University Hospital Carl Gustav Carus, University of Technology, Fetscherstr. 74, 10307 Dresden, Germany.
    • ,
  • Tobias Hölscher

      Affiliations

    • Department of Radiation Oncology and OncoRay Center for Radiation Research in Oncology, University of Technology, Dresden, Germany
    • ,
  • Jim Denham

      Affiliations

    • Prostate Cancer Trials Group based at Newcastle University, Australia

References 

  1. Aaltomaa SH, Kataja VV, Lahtinen T, et al. Eight years experience of local prostate cancer treatment with permanent I125 seed brachytherapy – morbidity and outcome results. Radiother Oncol. 2009;91:213–216
  2. Aizer AA, Yu JB, Colberg JW, et al. Radical prostatectomy vs. intensity-modulated radiation therapy in the management of localized prostate adenocarcinoma. Radiother Oncol. 2009;93:185–191
  3. Al Mamgani A, Heemsbergen WD, Levendag PC, et al. Subgroup analysis of patients with localized prostate cancer treated within the Dutch-randomized dose escalation trial. Radiother Oncol. 2010;96:13–18
  4. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005;293:2095–2101
  5. Alongi F, Fiorino C, Cozzarini C, et al. IMRT significantly reduces acute toxicity of whole-pelvis irradiation in patients treated with post-operative adjuvant or salvage radiotherapy after radical prostatectomy. Radiother Oncol. 2009;93:207–212
  6. Alvarez MJ, Koelbl O, Bogner L. Quasi-IMAT technique and secondary cancer risk in prostate cancer. Strahlenther Onkol. 2009;185:248–253
  7. Arcangeli G, Saracino B, Gomellini S, et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2010;
  8. Baumann M, Herrmann T, Koch R, et al. Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated vs conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC). EJC. 2009;S7:4;[Abstract]
  9. Baumann M, Krause M, Hill R. Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer. 2008;8:545–554
  10. Baumann M, Krause M, Thames H, et al. Cancer stem cells and radiotherapy. Int J Radiat Biol. 2009;85:391–402
  11. Baumann M, Liertz C, Baisch H, et al. Impact of overall treatment time of fractionated irradiation on local control of human FaDu squamous cell carcinoma in nude mice. Radiother Oncol. 1994;32:137–143
  12. Baumann M, Petersen C, Schulz P, et al. Impact of overall treatment time on local control of slow growing human GL squamous cell carcinoma in nude mice treated by fractionated irradiation. Radiother Oncol. 1999;50:107–111
  13. Beck-Bornholdt HP. Should tumors be clamped in radiobiological fractionation experiments?. Int J Radiat Oncol Biol Phys. 1991;21:675–682
  14. Beck-Bornholdt HP, Omniczynski M, Theis E, et al. Influence of treatment time on the response of rat rhabdomyosarcoma R1H to fractionated irradiation. Acta Oncol. 1991;30:57–63
  15. Bentzen SM, Ritter MA. The alpha/beta ratio for prostate cancer: what is it, really?. Radiother Oncol. 2005;76:1–3
  16. Bill-Axelson A, Holmberg L, Filen F, et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst. 2008;100:1144–1154
  17. Bolla M, de Reijke TM, Van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. 2009;360:2516–2527
  18. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997;337:295–300
  19. Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet. 2005;366:572–578
  20. Bourhis J, Overgaard J, Audry H, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet. 2006;368:843–854
  21. Brenner DJ. Fractionation and late rectal toxicity. Int J Radiat Oncol Biol Phys. 2004;60:1013–1015
  22. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 1999;43:1095–1101
  23. Brenner DJ, Martinez AA, Edmundson GK, et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys. 2002;52:6–13
  24. Bristow RG, Hill RP. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer. 2008;8:180–192
  25. Bristow RG, Ozcelik H, Jalali F, et al. Homologous recombination and prostate cancer: a model for novel DNA repair targets and therapies. Radiother Oncol. 2007;83:220–230
  26. Broggi S, Cozzarini C, Fiorino C, et al. Modeling set-up error by daily MVCT for prostate adjuvant treatment delivered in 20 fractions: implications for the assessment of the optimal correction strategies. Radiother Oncol. 2009;93:246–252
  27. Carnell DM, Smith RE, Daley FM, et al. An immunohistochemical assessment of hypoxia in prostate carcinoma using pimonidazole: implications for radioresistance. Int J Radiat Oncol Biol Phys. 2006;65:91–99
  28. Coote JH, Wylie JP, Cowan RA, et al. Hypofractionated intensity-modulated radiotherapy for carcinoma of the prostate: analysis of toxicity. Int J Radiat Oncol Biol Phys. 2009;74:1121–1127
  29. Cozzarini C, Fiorino C, Di Muzio N, et al. Hypofractionated adjuvant radiotherapy with helical tomotherapy after radical prostatectomy: planning data and toxicity results of a phase I–II study. Radiother Oncol. 2008;88:26–33
  30. D’Ambrosio DJ, Li T, Horwitz EM, et al. Does treatment duration affect outcome after radiotherapy for prostate cancer?. Int J Radiat Oncol Biol Phys. 2008;72:1402–1407
  31. D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer. 2002;95:281–286
  32. Dasu A. Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials?. Clin Oncol (R Coll Radiol). 2007;19:289–301
  33. Dearnaley DP, Hall E, Lawrence D, et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer. 2005;92:488–498
  34. Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2007;8:475–487
  35. Delouya G, Carrier JF, Beliveau-Nadeau D, et al. Migration of intraprostatic fiducial markers and its influence on the matching quality in external beam radiation therapy for prostate cancer. Radiother Oncol. 2010;96:43–47
  36. Denham JW, Kumar M, Gleeson PS, et al. Recognizing false biochemical failure calls after radiation with or without neo-adjuvant androgen deprivation for prostate cancer. Int J Radiat Oncol Biol Phys. 2009;74:404–411
  37. Denham JW, Steigler A, Wilcox C, et al. Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial. Lancet Oncol. 2008;9:1058–1068
  38. Denham JW, Steigler A, Wilcox C, et al. Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival?. Cancer. 2009;115:4477–4487
  39. Di Muzio N, Fiorino C, Cozzarini C, et al. Phase I–II study of hypofractionated simultaneous integrated boost with tomotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2009;74:392–398
  40. Dolezel M, Odrazka K, Vaculikova M, et al. Dose escalation in prostate radiotherapy up to 82Gy using simultaneous integrated boost: direct comparison of acute and late toxicity with 3D-CRT 74Gy and IMRT 78Gy. Strahlenther Onkol. 2010;186:197–202
  41. Duchesne GM, Peters LJ. What is the alpha/beta ratio for prostate cancer? Rationale for hypofractionated high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys. 1999;44:747–748
  42. Fenoglietto P, Laliberte B, Allaw A, et al. Persistently better treatment planning results of intensity-modulated (IMRT) over conformal radiotherapy (3D-CRT) in prostate cancer patients with significant variation of clinical target volume and/or organs-at-risk. Radiother Oncol. 2008;88:77–87
  43. Fowler JF. The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol. 2005;44:265–276
  44. Fowler JF, Ritter MA, Fenwick JD, et al. How low is the alpha/beta ratio for prostate cancer? In regard to Wang et al., IJROBP 2003;55:194–203. Int J Radiat Oncol Biol Phys. 2003;57:593–595
  45. Ghadjar P, Gwerder N, Madlung A, et al. Use of gold markers for setup in image-guided fractionated high-dose-rate brachytherapy as a monotherapy for prostate cancer. Strahlenther Onkol. 2009;185:731–735
  46. Ghadjar P, Matzinger O, Isaak B, et al. Association of urethral toxicity with dose exposure in combined high-dose-rate brachytherapy and intensity-modulated radiation therapy in intermediate- and high-risk prostate cancer. Radiother Oncol. 2009;91:237–242
  47. Hermesse J, Biver S, Jansen N, et al. A dosimetric selectivity intercomparison of HDR brachytherapy, IMRT and helical tomotherapy in prostate cancer radiotherapy. Strahlenther Onkol. 2009;185:736–742
  48. Herrmann T, Baumann M. Prolongation of latency or overall treatment time by unplanned radiation pauses. The clinical importance of compensation. Strahlenther Onkol. 2005;181:65–76
  49. Hessel F, Krause M, Helm A, et al. Differentiation status of human squamous cell carcinoma xenografts does not appear to correlate with the repopulation capacity of clonogenic tumour cells during fractionated irradiation. Int J Radiat Biol. 2004;80:719–727
  50. Hessel F, Krause M, Petersen C, et al. Repopulation of moderately well-differentiated and keratinizing GL human squamous cell carcinomas growing in nude mice. Int J Radiat Oncol Biol Phys. 2004;58:510–518
  51. Hessel F, Petersen C, Zips D, et al. Impact of increased cell loss on the repopulation rate during fractionated irradiation in human FaDu squamous cell carcinoma growing in nude mice. Int J Radiat Biol. 2003;79:479–486
  52. Hoskin PJ, Dearnaley DP. Hypofractionation in clinical trials for prostate cancer. Clin Oncol (R Coll Radiol). 2007;19:287–288
  53. Iori M, Cattaneo GM, Cagni E, et al. Dose–volume and biological-model based comparison between helical tomotherapy and (inverse-planned) IMAT for prostate tumours. Radiother Oncol. 2008;88:34–45
  54. Jereczek-Fossa BA, Fariselli L, Beltramo G, et al. Linac-based or robotic image-guided stereotactic radiotherapy for isolated lymph node recurrent prostate cancer. Radiother Oncol. 2009;93:14–17
  55. Jereczek-Fossa BA, Orecchia R. Evidence-based radiation oncology: definitive, adjuvant and salvage radiotherapy for non-metastatic prostate cancer. Radiother Oncol. 2007;84:197–215
  56. Jereczek-Fossa BA, Zerini D, Fodor C, et al. Acute toxicity of image-guided hypofractionated radiotherapy for prostate cancer: nonrandomized comparison with conventional fractionation. Urol Oncol 2010; in press.
  57. Junius S, Haustermans K, Bussels B, et al. Hypofractionated intensity modulated irradiation for localized prostate cancer, results from a phase I/II feasibility study. Radiat Oncol. 2007;2:29
  58. Kal HB, Van Gellekom MP. How low is the alpha/beta ratio for prostate cancer?. Int J Radiat Oncol Biol Phys. 2003;57:1116–1121
  59. Kalz J, Sterzing F, Schubert K, et al. Dosimetric comparison of image guidance by megavoltage computed tomography versus bone alignment for prostate cancer radiotherapy. Strahlenther Onkol. 2009;185:241–247
  60. Karlsdottir A, Muren LP, Wentzel-Larsen T, et al. Outcome in intermediate or high risk prostate cancer patients receiving radiation dose and hormone therapy. Acta Oncol. 2009;48:874–881
  61. Katz AJ, Santoro M, Ashley R, et al. Stereotactic body radiotherapy for organ-confined prostate cancer. BMC Urol. 2010;10:1
  62. Kim Y, Tome WA. Is it beneficial to selectively boost high-risk tumor subvolumes? A comparison of selectively boosting high-risk tumor subvolumes versus homogeneous dose escalation of the entire tumor based on equivalent EUD plans. Acta Oncol. 2008;47:906–916
  63. King CR, Brooks JD, Gill H, et al. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys. 2009;73:1043–1048
  64. Klotz L, Zhang L, Lam A, et al. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol. 2010;28:126–131
  65. Koppie TM, Grossfeld GD, Miller D, et al. Patterns of treatment of patients with prostate cancer initially managed with surveillance: results from The CaPSURE database. Cancer of the Prostate Strategic Urological Research Endeavor. J Urol. 2000;164:81–88
  66. Korreman S, Rasch C, McNair H, et al. The European Society of Therapeutic Radiology and Oncology-European Institute of Radiotherapy (ESTRO-EIR) report on 3D CT-based in-room image guidance systems: a practical and technical review and guide. Radiother Oncol. 2010;94:129–144
  67. Krakowsky Y, Loblaw A, Klotz L. Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics. J Urol. 2010;184:131–135
  68. Kron T, Thomas J, Fox C, et al. Intra-fraction prostate displacement in radiotherapy estimated from pre- and post-treatment imaging of patients with implanted fiducial markers. Radiother Oncol. 2010;95:191–197
  69. Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70:67–74
  70. Kupelian P, Kuban D, Thames H, et al. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995. Int J Radiat Oncol Biol Phys. 2005;61:415–419
  71. Kupelian PA, Ciezki J, Reddy CA, et al. Effect of increasing radiation doses on local and distant failures in patients with localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;71:16–22
  72. Lai PP, Perez CA, Shapiro SJ, et al. Carcinoma of the prostate stage B and C: lack of influence of duration of radiotherapy on tumor control and treatment morbidity. Int J Radiat Oncol Biol Phys. 1990;19:561–568
  73. Lai PP, Pilepich MV, Krall JM, et al. The effect of overall treatment time on the outcome of definitive radiotherapy for localized prostate carcinoma: the Radiation Therapy Oncology Group 75-06 and 77-06 experience. Int J Radiat Oncol Biol Phys. 1991;21:925–933
  74. Lim TS, Cheung PC, Loblaw DA, et al. Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: acute toxicity results. Int J Radiat Oncol Biol Phys. 2008;72:85–92
  75. Lu-Yao GL, Albertsen PC, Moore DF, et al. Outcomes of localized prostate cancer following conservative management. JAMA. 2009;302:1202–1209
  76. Madsen BL, Hsi RA, Pham HT, et al. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys. 2007;67:1099–1105
  77. Martin JM, Rosewall T, Bayley A, et al. Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma. Int J Radiat Oncol Biol Phys. 2007;69:1084–1089
  78. Marzi S, Saracino B, Petrongari MG, et al. Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer. J Exp Clin Cancer Res. 2009;28:117
  79. Mendenhall WM, Henderson RH, Mendenhall NP. Definitive radiotherapy for prostate cancer. Am J Clin Oncol. 2008;31:496–503
  80. Meng AX, Jalali F, Cuddihy A, et al. Hypoxia down-regulates DNA double strand break repair gene expression in prostate cancer cells. Radiother Oncol. 2005;76:168–176
  81. Milosevic M, Chung P, Parker C, et al. Androgen withdrawal in patients reduces prostate cancer hypoxia: implications for disease progression and radiation response. Cancer Res. 2007;67:6022–6025
  82. Morgan SC, Waldron TS, Eapen L, et al. Adjuvant radiotherapy following radical prostatectomy for pathologic T3 or margin-positive prostate cancer: a systematic review and meta-analysis. Radiother Oncol. 2008;88:1–9
  83. Munro NP, Al Qaisieh B, Bownes P, et al. Outcomes from Gleason 7, intermediate risk, localized prostate cancer treated with Iodine-125 monotherapy over 10years. Radiother Oncol. 2010;96:34–37
  84. Nairz O, Merz F, Deutschmann H, et al. A strategy for the use of image-guided radiotherapy (IGRT) on linear accelerators and its impact on treatment margins for prostate cancer patients. Strahlenther Onkol. 2008;184:663–667
  85. Nanda A, D’Amico AV. Combined radiation and hormonal therapy or dose escalation for men with unfavourable-risk prostate cancer: an evidence-based approach using a synthesis of randomized clinical trials. BJU Int. 2008;102:1366–1368
  86. Nobes JP, Khaksar SJ, Hawkins MA, et al. Novel prostate brachytherapy technique: improved dosimetric and clinical outcome. Radiother Oncol. 2008;88:121–126
  87. Norkus D, Miller A, Kurtinaitis J, et al. A randomized trial comparing hypofractionated and conventionally fractionated three-dimensional external-beam radiotherapy for localized prostate adenocarcinoma: a report on acute toxicity. Strahlenther Onkol. 2009;185:715–721
  88. Parker C. Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol. 2004;5:101–106
  89. Parker C, Milosevic M, Toi A, et al. Polarographic electrode study of tumor oxygenation in clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2004;58:750–757
  90. Pasquier D, Ballereau C. Adjuvant and salvage radiotherapy after prostatectomy for prostate cancer: a literature review. Int J Radiat Oncol Biol Phys. 2008;72:972–979
  91. Peeters A, Grutters JP, Pijls-Johannesma M, et al. How costly is particle therapy? Cost analysis of external beam radiotherapy with carbon-ions, protons and photons. Radiother Oncol. 2010;95:45–53
  92. Peeters ST, Heemsbergen WD, van Putten WL, et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68Gy to 78Gy. Int J Radiat Oncol Biol Phys. 2005;61:1019–1034
  93. Peeters STH, Lebesque JV, Heemsbergen WD, et al. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2006;64:1151–1161
  94. Peeters STH, Heemsbergen WD, Koper PCM, et al. Dose–response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68Gy of radiotherapy with 78Gy. J Clin Oncol. 2006;24:1990–1996
  95. Petersen C, Zips D, Krause M, et al. Repopulation of FaDu human squamous cell carcinoma during fractionated radiotherapy correlates with reoxygenation. Int J Radiat Oncol Biol Phys. 2001;51:483–493
  96. Pieters BR, de Back DZ, Koning CC, et al. Comparison of three radiotherapy modalities on biochemical control and overall survival for the treatment of prostate cancer: a systematic review. Radiother Oncol. 2009;93:168–173
  97. Pieters BR, van de Kamer JB, van Herten YR, et al. Comparison of biologically equivalent dose–volume parameters for the treatment of prostate cancer with concomitant boost IMRT versus IMRT combined with brachytherapy. Radiother Oncol. 2008;88:46–52
  98. Pinkawa M, Attieh C, Piroth MD, et al. Dose-escalation using intensity-modulated radiotherapy for prostate cancer – evaluation of the dose distribution with and without 18F-choline PET-CT detected simultaneous integrated boost. Radiother Oncol. 2009;93:213–219
  99. Pinkawa M, Piroth MD, Asadpour B, et al. Neoadjuvant hormonal therapy and external-beam radiotherapy versus external-beam irradiation alone for prostate cancer. A quality-of-life analysis. Strahlenther Onkol. 2009;185:101–108
  100. Pollack A, Hanlon AL, Horwitz EM, et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys. 2006;64:518–526
  101. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53:1097–1105
  102. Ritter M. Rationale, conduct, and outcome using hypofractionated radiotherapy in prostate cancer. Semin Radiat Oncol. 2008;18:249–256
  103. Ritter M, Forman J, Kupelian P, et al. Hypofractionation for prostate cancer. Cancer J. 2009;15:1–6
  104. Rosewall T, Kong V, Vesprini D, et al. Prostate delineation using CT and MRI for radiotherapy patients with bilateral hip prostheses. Radiother Oncol. 2009;90:325–330
  105. Rothe AM, Eilertsen K, Malinen E. Optimal treatment margins for radiotherapy of prostate cancer based on interfraction imaging. Acta Oncol. 2008;47:1373–1381
  106. Sanguineti G, Endres EJ, Parker BC, et al. Acute toxicity of whole-pelvis IMRT in 87 patients with localized prostate cancer. Acta Oncol. 2008;47:301–310
  107. Saunders M, Dische S, Barrett A, et al. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee. Lancet. 1997;350:161–165
  108. Seppala J, Seppanen M, Arponen E, et al. Carbon-11 acetate PET/CT based dose escalated IMRT in prostate cancer. Radiother Oncol. 2009;93:234–240
  109. Seppenwoolde Y, Kolkman-Deurloo IK, Sipkema D, et al. HDR prostate monotherapy: dosimetric effects of implant deformation due to posture change between. Radiother Oncol. 2008;86:114–119
  110. Shao YH, Demissie K, Shih W, et al. Contemporary risk profile of prostate cancer in the United States. J Natl Cancer Inst. 2009;101:1280–1283
  111. Smeenk RJ, van Lin EN, van Kollenburg P, et al. Anal wall sparing effect of an endorectal balloon in 3D conformal and intensity-modulated prostate radiotherapy. Radiother Oncol. 2009;93:131–136
  112. Soete G, Arcangeli S, De Meerleer G, et al. Phase II study of a four-week hypofractionated external beam radiotherapy regimen for prostate cancer: report on acute toxicity. Radiother Oncol. 2006;80:78–81
  113. South CP, Khoo VS, Naismith O, et al. A comparison of treatment planning techniques used in two randomised UK external beam radiotherapy trials for localised prostate cancer. Clin Oncol (R Coll Radiol). 2008;20:15–21
  114. Sterzing F, Schubert K, Sroka-Perez G, et al. Helical tomotherapy. Experiences of the first 150 patients in Heidelberg. Strahlenther Onkol. 2008;184:8–14
  115. Suit HD, Howes AE, Hunter N. Dependence of response of a C3H mammary carcinoma to fractionated irradiation on fractionation number and intertreatment interval. Radiat Res. 1977;72:440–454
  116. Supiot S, Shubbar S, Fleshner N, et al. A phase I trial of pre-operative radiotherapy for prostate cancer: clinical and translational studies. Radiother Oncol. 2008;88:53–60
  117. Thames HD, Kuban D, Levy LB, et al. The role of overall treatment time in the outcome of radiotherapy of prostate cancer: an analysis of biochemical failure in 4839 men treated between 1987 and 1995. Radiother Oncol. 2010;96:6–12
  118. Thames HD, Ruifrok AC, Milas L, et al. Accelerated repopulation during fractionated irradiation of a murine ovarian carcinoma: downregulation of apoptosis as a possible mechanism. Int J Radiat Oncol Biol Phys. 1996;35:951–962
  119. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009;181:956–962
  120. Townsend NC, Huth BJ, Ding W, et al. Acute toxicity after CyberKnife-delivered hypofractionated radiotherapy for treatment of prostate cancer. Am J Clin Oncol 2010; in press.
  121. Trott KR, Kummermehr J. Rapid repopulation in radiotherapy: a debate on mechanism. Accelerated repopulation in tumours and normal tissues. Radiother Oncol. 1991;22:159–160
  122. Turrisi AT, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999;340:265–271
  123. Urano M, Nishimura Y, Kuroda M, et al. Are hypoxic cells critical for the outcome of fractionated radiotherapy in a slow-growing mouse tumor?. Radiother Oncol. 1998;48:221–228
  124. Urano M, Nishimura Y, Yaes R. The relative significance of repopulation and hypoxic clonogens in the fractionated radiotherapy of a mouse tumor. Radiat Res. 1995;142:204–211
  125. van den Bergh RC, Vasarainen H, van der Poel HG, et al. Short-term outcomes of the prospective multicentre ‘Prostate Cancer Research International: Active Surveillance’ study. BJU Int. 2010;105:956–962
  126. van den Bosch MR, Lips IM, Lagerburg V, et al. Feasibility of adequate dose coverage in permanent prostate brachytherapy using divergent needle insertion methods. Radiother Oncol. 2008;86:120–125
  127. van der Kogel AJ. Radiation response and tolerance of normal tissues. In:  Steel GG editors. Basic clinical radiobiology. London: Arnold; 2002;p. 30–41
  128. van Haaren PM, Bel A, Hofman P, et al. Influence of daily setup measurements and corrections on the estimated delivered dose during IMRT treatment of prostate cancer patients. Radiother Oncol. 2009;90:291–298
  129. van Herten YR, van de Kamer JB, van Wieringen N, et al. Dosimetric evaluation of prostate rotations and their correction by couch rotations. Radiother Oncol. 2008;88:156–162
  130. Wang H, Vees H, Miralbell R, et al. 18F-fluorocholine PET-guided target volume delineation techniques for partial prostate re-irradiation in local recurrent prostate cancer. Radiother Oncol. 2009;93:220–225
  131. Wang JZ, Guerrero M, Li XA. How low is the alpha/beta ratio for prostate cancer?. Int J Radiat Oncol Biol Phys. 2003;55:194–203
  132. Wang JZ, Li XA, Yu CX, et al. The low alpha/beta ratio for prostate cancer: what does the clinical outcome of HDR brachytherapy tell us?. Int J Radiat Oncol Biol Phys. 2003;57:1101–1108
  133. Widmark A, Klepp Or, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. 2009;373:301–308
  134. Wiegel T, Bottke D, Steiner U, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol. 2009;27:2924–2930
  135. Williams SG, Taylor JM, Liu N, et al. Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer. Int J Radiat Oncol Biol Phys. 2007;68:24–33
  136. Withers HR. Biologic basis for altered fractionation schemes. Cancer. 1985;55:2086–2095
  137. Withers HR, Taylor JM, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol. 1988;27:131–146
  138. Wolff D, Stieler F, Welzel G, et al. Volumetric modulated arc therapy (VMAT) vs. serial tomotherapy, step-and-shoot IMRT and 3D-conformal RT for treatment of prostate cancer. Radiother Oncol. 2009;93:226–233
  139. Yassa M, Fortin B, Fortin MA, et al. Combined hypofractionated radiation and hormone therapy for the treatment of intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2008;71:58–63
  140. Yeoh EE, Holloway RH, Fraser RJ, et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. Int J Radiat Oncol Biol Phys. 2006;66:1072–1083
  141. Zelefsky MJ, Fuks Z, Hunt M, et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys. 2002;53:1111–1116
  142. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005;294:1233–1239
  143. Zietman AL, Bae K, Slater JD, et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton Radiation Oncology Group/American College of Radiology 95-09. J Clin Oncol. 2010;28:1106–1111
  144. Zilli T, Rouzaud M, Jorcano S, et al. Dose escalation study with two different hypofractionated intensity modulated radiotherapy techniques for localized prostate cancer: acute toxicity. Technol Cancer Res Treat. 2010;9:263–270

PII: S0167-8140(10)00339-7

doi: 10.1016/j.radonc.2010.06.001

Radiotherapy & Oncology
Volume 96, Issue 1 , Pages 1-5 , July 2010

Article Tools